FDA official logo
GSRS logo
PFDA official logo

RELATLIMAB

  • UNII: AF75XOF6W3
  • Preferred Substance Name: RELATLIMAB

  • 1673516-98-7
  • BMS-986016
  • BMS-986213 COMPONENT RELATLIMAB
  • IMMUNOGLOBULIN G4, ANTI-(HUMAN LYMPHOCYTE ACTIVATION GENE-3 PROTEIN) (HUMAN HEAVY CHAIN), DISULFIDE WITH HUMAN LIGHT CHAIN, DIMER
  • IMMUNOGLOBULIN G4-KAPPA, ANTI-(HUMAN LYMPHOCYTE ACTIVATION GENE 3 PROTEIN (LAG-3, PROTEIN FDC, CD223 ANTIGEN))
  • OPDUALAG COMPONENT RELATLIMAB-RMBW
  • RELATLIMAB [INN]
  • RELATLIMAB [USAN]
  • RELATLIMAB [WHO-DD]
  • RELATLIMAB RMBW [WHO-DD]
  • RELATLIMAB-RMBW

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.




About, Contact Us, Copyright, Privacy, Accessibility

U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993-0002

U.S. Food and Drug Administration, Health & Human Services

Freedom of Information Act

Powered by

DNAnexus official logo